search
Back to results

Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback

Primary Purpose

Parkinson Disease

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Open Loop DBS
Adaptive (Closed Loop) DBS
Intermittent Open Loop DBS
Sponsored by
Stanford University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinically-established PD
  • Meets criteria for STN DBS eligibility as part of patient's standard medical care
  • The presence of complications of medication such as wearing off signs, fluctuating responses and/or dyskinesias, and/or medication refractory tremor, and/or impairment in the quality of life on or off medication due to these factors.
  • Ability and willingness to return for study visits, at the initial programming and after three, six and twelve months of DBS.
  • Age > 25
  • Freezing of gait questionnaire (FOG-Q) score ≥ 1 and/or gait sub-score (Item 3.10) of MDS- UPDRS III ≥ 1

Exclusion Criteria:

  • Dementia
  • Untreated psychiatric disease
  • Hoehn and Yahr stage 5 on or off medication (non-ambulatory)
  • Age > 80
  • Major surgical morbidities such as severe hypertension, coagulopathy and certain metabolic conditions that might increase the risk of hemorrhage or other surgical complications
  • Presence of a cardiac pacemaker/defibrillator
  • Inability to understand/sign consent
  • Requires rTMS, ECT, MRI, or diathermy
  • Are pregnant or lactating
  • Has a cranial metallic implant
  • History of seizures or epilepsy

Sites / Locations

  • Stanford UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Device: Summit RC+S

Device: Percept PC

Arm Description

Open Loop DBS: Standard DBS therapy at a constant frequency and voltage Adaptive (Closed Loop) DBS: DBS that responds to neural or kinematic features of patient's current state Intermittent Open Loop DBS: Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.

Open Loop DBS: Standard DBS therapy at a constant frequency and voltage Adaptive (Closed Loop) DBS: DBS that responds to neural features of patient's current state

Outcomes

Primary Outcome Measures

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to Stimulation Condition
A Customized Adverse Events and Tolerability Questionnaire will measure the absence/presence and frequency of paresthesias, and muscle twitching relative to each stimulation condition
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to quality of life
The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IV will: (I) Evaluate mentation, behavior, and mood (II) Evaluate a patient's activities of daily life (IV) Measure the presence/severity of dyskinesias and other complications of therapy over time
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to speech
The Speech Intelligibility Test (SIT) will measure changes in speech related to each stimulation condition.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to gait
The Freezing of Gait Questionnaire (FOG-Q) will be used to record changes in gait over time

Secondary Outcome Measures

Gait Parameters: Arrhythmicity
Variability in stride time during a gait task
Gait Parameters: Mean Shank Angular Velocity
Average of the peak shank angular velocities of every stride during the gait task
Gait Parameters: Mean Gait Cycle Time
Average length of time of each stride during a gait task
Percent Time Freezing
The percentage of the gait task was a participant frozen
The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
Portion of the scale assesses the motor signs of PD. Each item is scored on a scale from 0 (normal) to 4 (severe), with the total possible score ranging from 0 to 132.

Full Information

First Posted
July 30, 2019
Last Updated
July 28, 2023
Sponsor
Stanford University
search

1. Study Identification

Unique Protocol Identification Number
NCT04043403
Brief Title
Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback
Official Title
Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 28, 2019 (Actual)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
July 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Deep Brain Stimulation of the subthalamic nucleus (STN) has become a standard of care, FDA-approved treatment for Parkinson's disease, with stimulation delivered at a constant amplitude and voltage, operating in an open-loop fashion that does not respond to a patient's current state. Although gait deficits and freezing of gait may initially respond to continuous open-loop deep brain stimulation (olDBS) and medication, the symptoms often recur over time. The episodic and predictable nature of FOG makes it well suited for adaptive DBS (aDBS) and a device that overcomes the limitations of traditional high frequency olDBS and is capable of adapting therapy either in the frequency or intensity domain transiently to treat FOG while also treating other PD signs such as tremor and bradykinesia. The purpose of this study is to determine the feasibility of an adaptive DBS system, that responds to patient-specific neural and kinematic variables with customized DBS parameters.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will have either the Percept PC system, or Summit RC+S system from Medtronic PLC implanted.
Masking
ParticipantOutcomes Assessor
Allocation
Non-Randomized
Enrollment
14 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Device: Summit RC+S
Arm Type
Experimental
Arm Description
Open Loop DBS: Standard DBS therapy at a constant frequency and voltage Adaptive (Closed Loop) DBS: DBS that responds to neural or kinematic features of patient's current state Intermittent Open Loop DBS: Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
Arm Title
Device: Percept PC
Arm Type
Experimental
Arm Description
Open Loop DBS: Standard DBS therapy at a constant frequency and voltage Adaptive (Closed Loop) DBS: DBS that responds to neural features of patient's current state
Intervention Type
Device
Intervention Name(s)
Open Loop DBS
Intervention Description
Standard DBS therapy at a constant frequency and voltage
Intervention Type
Device
Intervention Name(s)
Adaptive (Closed Loop) DBS
Intervention Description
DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state
Intervention Type
Device
Intervention Name(s)
Intermittent Open Loop DBS
Intervention Description
Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
Primary Outcome Measure Information:
Title
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to Stimulation Condition
Description
A Customized Adverse Events and Tolerability Questionnaire will measure the absence/presence and frequency of paresthesias, and muscle twitching relative to each stimulation condition
Time Frame
3 Months
Title
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to quality of life
Description
The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IV will: (I) Evaluate mentation, behavior, and mood (II) Evaluate a patient's activities of daily life (IV) Measure the presence/severity of dyskinesias and other complications of therapy over time
Time Frame
3 Months
Title
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to speech
Description
The Speech Intelligibility Test (SIT) will measure changes in speech related to each stimulation condition.
Time Frame
6 Months
Title
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to gait
Description
The Freezing of Gait Questionnaire (FOG-Q) will be used to record changes in gait over time
Time Frame
3 Months
Secondary Outcome Measure Information:
Title
Gait Parameters: Arrhythmicity
Description
Variability in stride time during a gait task
Time Frame
Collected up to 10 days every 3 months
Title
Gait Parameters: Mean Shank Angular Velocity
Description
Average of the peak shank angular velocities of every stride during the gait task
Time Frame
Collected up to 10 days every 3 months
Title
Gait Parameters: Mean Gait Cycle Time
Description
Average length of time of each stride during a gait task
Time Frame
Collected up to 10 days every 3 months
Title
Percent Time Freezing
Description
The percentage of the gait task was a participant frozen
Time Frame
Collected up to 10 days every 3 months
Title
The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
Description
Portion of the scale assesses the motor signs of PD. Each item is scored on a scale from 0 (normal) to 4 (severe), with the total possible score ranging from 0 to 132.
Time Frame
Collected up to 10 days every 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinically-established PD Meets criteria for STN DBS eligibility as part of patient's standard medical care or already implanted in the STN with Percept(TM) PC The presence of complications of medication such as wearing off signs, fluctuating responses and/or dyskinesias, and/or medication refractory tremor, and/or impairment in the quality of life on or off medication due to these factors. Ability and willingness to return for study visits, at the initial programming and after three, six and twelve months of DBS. Age > 18 Freezing of gait questionnaire (FOG-Q) score ≥ 1 and/or gait sub-score (Item 3.10) of MDS- UPDRS III ≥ 1 Greater than or equal to 1.2 microVp between 8-35 Hz on either the LSTN or RSTN (Percept (TM) PC cohort only) Exclusion Criteria: Dementia Untreated psychiatric disease Hoehn and Yahr stage 5 on or off medication (non-ambulatory) Age > 80 Major surgical morbidities such as severe hypertension, coagulopathy and certain metabolic conditions that might increase the risk of hemorrhage or other surgical complications Presence of a cardiac pacemaker/defibrillator Inability to understand/sign consent Requires rTMS, ECT, MRI (Summit(R) RC+S cohort only), or diathermy Are pregnant or lactating Has a cranial metallic implant History of seizures or epilepsy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Helen Bronte-Stewart, MD MSE
Phone
6507232116
Email
bronte-stewart-lab@stanford.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helen M. Bronte-Stewart, MD,MSE
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sudeep Aditham
Phone
650-723-6709
Email
bronte-stewart-lab@stanford.edu
First Name & Middle Initial & Last Name & Degree
Helen M Bronte-Stewart, MD MSE

12. IPD Sharing Statement

Learn more about this trial

Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback

We'll reach out to this number within 24 hrs